These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Autoantibodies in Myasthenia Gravis]. Higuchi O Brain Nerve; 2018 Apr; 70(4):419-426. PubMed ID: 29632289 [TBL] [Abstract][Full Text] [Related]
44. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis. Sato T; Ishigaki Y; Komiya T; Tsuda H Ann N Y Acad Sci; 1988; 540():554-6. PubMed ID: 3061349 [No Abstract] [Full Text] [Related]
46. Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection. Hwang B; Lee SW Biochem Biophys Res Commun; 2002 Jan; 290(2):656-62. PubMed ID: 11785949 [TBL] [Abstract][Full Text] [Related]
47. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis. Takamori M; Ide Y Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553 [TBL] [Abstract][Full Text] [Related]
48. Expression of a highly antigenic and native-like folded extracellular domain of the human α1 subunit of muscle nicotinic acetylcholine receptor, suitable for use in antigen specific therapies for Myasthenia Gravis. Niarchos A; Zouridakis M; Douris V; Georgostathi A; Kalamida D; Sotiriadis A; Poulas K; Iatrou K; Tzartos SJ PLoS One; 2013; 8(12):e84791. PubMed ID: 24376846 [TBL] [Abstract][Full Text] [Related]
49. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867 [TBL] [Abstract][Full Text] [Related]
50. Selective removal of anti-acetylcholine receptor antibodies and IgG in vitro with an immunoadsorbent containing immobilized sulfathiazole. Yamamoto Y; Sameshima T; Akaike T Artif Organs; 1990 Oct; 14(5):334-41. PubMed ID: 2241600 [TBL] [Abstract][Full Text] [Related]
56. Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor. Cardona A; Pritsch O; Dumas G; Bach JF; Dighiero G Mol Immunol; 1995 Nov; 32(16):1215-23. PubMed ID: 8559146 [TBL] [Abstract][Full Text] [Related]
57. Morphological effects of myasthenia gravis patient sera on human muscle cells. Luckman SP; Skeie GO; Helgeland G; Gilhus NE Muscle Nerve; 2006 Jan; 33(1):93-103. PubMed ID: 16228972 [TBL] [Abstract][Full Text] [Related]
58. Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region. Luo J; Lindstrom J J Mol Neurosci; 2010 Jan; 40(1-2):217-20. PubMed ID: 19705087 [TBL] [Abstract][Full Text] [Related]
59. Molecular modeling of the complex between Torpedo acetylcholine receptor and anti-MIR Fab198. Konstantakaki M; Tzartos SJ; Poulas K; Eliopoulos E Biochem Biophys Res Commun; 2007 May; 356(3):569-75. PubMed ID: 17376405 [TBL] [Abstract][Full Text] [Related]
60. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]